Article
Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance
2023-09-16
Abstract excerpt
<h4>ABSTRACT</h4> Chimeric antigen receptors (CARs) reprogram T cells to recognize and target cancer cells. Despite remarkable responses observed with CAR-T cell therapy in patients with hematological malignancies, CAR-T cell engineering still relies mostly on randomly integrating vectors, limiting the possibilities of fine-tuning T cell function. Here, we designed a CRISPR-based marker-free selection strategy to...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 8a21a7dd-ad2b-5ee3-9c61-cc7bb92fad08
- DOI
- 10.1101/2023.09.14.557485
